Aspire Biopharma Holdings (ASBP) Interest Coverage Ratio (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Interest Coverage Ratio came in at 1.03 in Q1 2026, up 98.08% year-over-year from 0.52 in Q1 2025, and down 247.79% quarter-over-quarter from 0.3 in Q4 2025.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Interest Coverage Ratio (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Interest Coverage Ratio for 2 consecutive years, with 1.03 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 98.08% year-over-year to 1.03 in Q1 2026; TTM through Jun 2026 was 0.79, a N/A change from a year earlier, with the FY2025 full-year figure at 2.27, up 81.64% from the prior year.
- Interest Coverage Ratio was 1.03 for Q1 2026 at Aspire Biopharma Holdings, down from 0.3 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.3 in Q4 2025 and troughed at 53.66 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 117.59 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 493.00 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 |
| Dec 31, 2025 | -0.30 |
| Sep 30, 2025 | -0.77 |
| Jun 30, 2025 | -1.52 |
| Mar 31, 2025 | -53.66 |